"Study","Study.year","Analysis.name","Analysis.number","Subgroup.number","Experimental.cases","Experimental.N","Control.cases","Control.N","Experimental.mean","Experimental.SD","Control.mean","Control.SD","GIV.Mean","GIV.SE","Mean","CI.start","CI.end","Variance","Weight","analysis_key","dataset_name","exp_cases_gt_n","ctrl_cases_gt_n","exp_cases_lt0","ctrl_cases_lt0","exp_n_le0","ctrl_n_le0","exp_cases_nonint","ctrl_cases_nonint","exp_n_nonint","ctrl_n_nonint","double_zero","all_events","sparse_events","exp_sd_le0","ctrl_sd_le0","variance_negative","giv_se_negative","ci_inverted","ci_mismatch"
"An 2020",2020,"Mortality during follow-up (for all studies)",1,NA,1,32,3,34,0,0,0,0,0,0,0.354167,0.03881,3.232001,0,0.878549,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Blauenfeldt 2023",2023,"Mortality during follow-up (for all studies)",1,NA,38,436,47,466,0,0,0,0,0,0,0.864142,0.575126,1.298397,0,25.233236,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chen 2022",2022,"Mortality during follow-up (for all studies)",1,NA,7,863,10,913,0,0,0,0,0,0,0.740556,0.28316,1.936794,0,4.628393,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2017",2017,"Mortality during follow-up (for all studies)",1,NA,0,13,0,13,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"England 2019",2019,"Mortality during follow-up (for all studies)",1,NA,2,31,4,29,0,0,0,0,0,0,0.467742,0.092557,2.36377,0,1.635099,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Guo 2025",2025,"Mortality during follow-up (for all studies)",1,NA,11,268,5,264,0,0,0,0,0,0,2.167164,0.763414,6.152104,0,3.932534,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"He 2020",2020,"Mortality during follow-up (for all studies)",1,NA,0,24,1,25,0,0,0,0,0,0,0.346667,0.014808,8.115524,0,0.432207,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"He 2022",2022,"Mortality during follow-up (for all studies)",1,NA,0,63,1,63,0,0,0,0,0,0,0.333333,0.013837,8.030017,0,0.424468,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hou 2022",2022,"Mortality during follow-up (for all studies)",1,NA,79,1517,84,1516,0,0,0,0,0,0.163908868237006,0.939856,0.697087,1.267173,0.0268661170867361,45.784912,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hougaard 2014",2014,"Mortality during follow-up (for all studies)",1,NA,5,133,1,91,0,0,0,0,0,0,3.421053,0.406381,28.799554,0,0.94628,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Landman 2023",2023,"Mortality during follow-up (for all studies)",1,NA,2,31,5,40,0,0,0,0,0,0,0.516129,0.107236,2.484143,0,1.737981,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Mortality during follow-up (for all studies)",1,NA,6,37,15,40,0,0,0,0,0,0,0.432432,0.187705,0.996232,0,6.132173,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pico 2020",2020,"Mortality during follow-up (for all studies)",1,NA,14,90,10,91,0,0,0,0,0,0,1.415556,0.663738,3.018958,0,7.434878,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Poalelungi 2021",2021,"Mortality during follow-up (for all studies)",1,NA,2,18,1,22,0,0,0,0,0,0,2.444444,0.240651,24.829731,0,0.79929,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Zhang 2022",2022,"Mortality during follow-up (for all studies)",1,NA,0,18,0,22,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Blauenfeldt 2023",2023,"Recurrence of ischemic stroke at the endpoint (for all studies)",1,NA,22,377,27,393,0,0,0,0,0,0.295949975887905,0.849396,0.492561,1.464739,0.0875863882280514,7.390181,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Che 2019",2019,"Recurrence of ischemic stroke at the endpoint (for all studies)",1,NA,0,15,1,15,0,0,0,0,0,0,0.333333,0.01465,7.584305,0,0.230999,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chen 2022",2022,"Recurrence of ischemic stroke at the endpoint (for all studies)",1,NA,7,863,6,913,0,0,0,0,0,0,1.23426,0.416456,3.658004,0,1.898719,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2017",2017,"Recurrence of ischemic stroke at the endpoint (for all studies)",1,NA,0,13,2,13,0,0,0,0,0,0,0.2,0.010525,3.800646,0,0.260089,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2019",2019,"Recurrence of ischemic stroke at the endpoint (for all studies)",1,NA,2,31,6,29,0,0,0,0,0,0.74234444082057,0.311828,0.068331,1.423024,0.551075268817204,0.975902,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Guo 2025",2025,"Recurrence of ischemic stroke at the endpoint (for all studies)",1,NA,35,270,34,266,0,0,0,0,0,0,1.014161,0.652808,1.575538,0,11.141844,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"He 2020",2020,"Recurrence of ischemic stroke at the endpoint (for all studies)",1,NA,1,24,0,25,0,0,0,0,0,0,3.12,0.133275,73.039718,0,0.226849,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hou 2022",2022,"Recurrence of ischemic stroke at the endpoint (for all studies)",1,NA,257,1517,288,1516,0,0,0,0,0,0.10270963001169,0.891773,0.765732,1.038561,0.0105492680971382,71.092822,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kerstens 2023",2023,"Recurrence of ischemic stroke at the endpoint (for all studies)",1,NA,3,40,6,48,0,0,0,0,0,0,0.6,0.160144,2.247978,0,1.287581,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2018",2018,"Recurrence of ischemic stroke at the endpoint (for all studies)",1,NA,0,29,2,31,0,0,0,0,0,0,0.213333,0.010672,4.264527,0,0.25138,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2020",2020,"Recurrence of ischemic stroke at the endpoint (for all studies)",1,NA,2,24,4,24,0,0,0,0,0,0,0.5,0.100918,2.477269,0,0.878528,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Recurrence of ischemic stroke at the endpoint (for all studies)",1,NA,1,37,5,40,0,0,0,0,0,0,0.216216,0.026478,1.765612,0,0.510902,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Meng 2012",2012,"Recurrence of ischemic stroke at the endpoint (for all studies)",1,NA,2,38,7,30,0,0,0,0,0,0,0.225564,0.050492,1.007664,0,1.00377,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Meng 2012",2012,"Recurrence of ischemic stroke at the endpoint (for all studies)",1,NA,3,38,8,30,0,0,0,0,0,0,0.296053,0.085883,1.02054,0,1.465773,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Meng 2015",2015,"Recurrence of ischemic stroke at the endpoint (for all studies)",1,NA,2,30,5,28,0,0,0,0,0,0.875224151870431,0.373333,0.078698,1.771037,0.766017316017316,0.928081,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Poalelungi 2021",2021,"Recurrence of ischemic stroke at the endpoint (for all studies)",1,NA,1,18,0,22,0,0,0,0,0,0,3.631579,0.156808,84.105266,0,0.228405,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Zhang 2022",2022,"Recurrence of ischemic stroke at the endpoint (for all studies)",1,NA,0,19,1,22,0,0,0,0,0,0,0.383333,0.016525,8.892066,0,0.228172,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Blauenfeldt 2023",2023,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,1,22,436,27,393,0,0,0,0,0,0.295553767026986,0.734455,0.425369,1.268131,0.0873520292038416,11.787432,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2017",2017,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,1,0,13,2,13,0,0,0,0,0,0,0.2,0.010525,3.800646,0,0.477379,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2019",2019,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,1,2,31,6,29,0,0,0,0,0,0.931566472107076,0.311828,0.068331,1.423024,0.867816091954023,1.765292,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Guo 2025",2025,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,1,35,270,34,266,0,0,0,0,0,0,1.014161,0.652808,1.575538,0,16.718617,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"He 2020",2020,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,1,1,24,0,25,0,0,0,0,0,0,3.12,0.133275,73.039718,0,0.416653,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kerstens 2023",2023,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,1,3,40,6,48,0,0,0,0,0,0,0.6,0.160144,2.247978,0,2.3145,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2018",2018,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,1,0,29,2,31,0,0,0,0,0,0,0.213333,0.010672,4.264527,0,0.461476,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2020",2020,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,1,2,24,4,24,0,0,0,0,0,0,0.5,0.100918,2.477269,0,1.592287,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Poalelungi 2021",2021,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,1,1,18,0,22,0,0,0,0,0,0,3.631579,0.156808,84.105266,0,0.419497,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Che 2019",2019,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,2,0,15,1,15,0,0,0,0,0,0,0.333333,0.01465,7.584305,0,0.424239,"2::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chen 2022",2022,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,2,7,863,6,913,0,0,0,0,0,0,1.23426,0.416456,3.658004,0,3.371663,"2::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hou 2022",2022,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,2,257,1517,288,1516,0,0,0,0,0,0.0947167136628357,0.891773,0.765732,1.038561,0.0089712558470876,53.197529,"2::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,2,1,37,5,40,0,0,0,0,0,0,0.216216,0.026478,1.765612,0,0.932931,"2::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Meng 2012",2012,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,2,3,38,8,30,0,0,0,0,0,0,0.296053,0.085883,1.02054,0,2.625413,"2::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Meng 2012",2012,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,2,2,38,7,30,0,0,0,0,0,0,0.225564,0.050492,1.007664,0,1.81468,"2::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Meng 2015",2015,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,2,2,30,5,28,0,0,0,0,0,0,0.373333,0.078698,1.771037,0,1.680414,"2::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Che 2019",2019,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention with reperfusion therapy)",3,1,0,15,1,15,0,0,0,0,0,1.67336436944866,0.333333,0.01465,7.584305,2.8001483129403,0.693077,"3::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2019",2019,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention with reperfusion therapy)",3,1,1,16,3,17,0,0,0,0,0,1.21302455516307,0.354167,0.040936,3.064126,1.47142857142857,1.436037,"3::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Guo 2025",2025,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention with reperfusion therapy)",3,1,35,270,34,266,0,0,0,0,0,0,1.014161,0.652808,1.575538,0,22.578012,"3::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"He 2020",2020,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention with reperfusion therapy)",3,1,1,24,0,25,0,0,0,0,0,1.65784062696947,3.12,0.133275,73.039718,2.74843554443054,0.68075,"3::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chen 2022",2022,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention with reperfusion therapy)",3,2,7,863,6,913,0,0,0,0,0,0.558385681814362,1.23426,0.416456,3.658004,0.311794569655289,5.306945,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2017",2017,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention with reperfusion therapy)",3,2,0,13,2,13,0,0,0,0,0,1.60032202878458,0.2,0.010525,3.800646,2.5610305958132,0.779358,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2019",2019,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention with reperfusion therapy)",3,2,1,15,3,12,0,0,0,0,0,1.23120794989028,0.266667,0.031624,2.248616,1.51587301587302,1.470022,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hou 2022",2022,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention with reperfusion therapy)",3,2,257,1517,288,1516,0,0,0,0,0,0.0947167136628357,0.891773,0.765732,1.038561,0.0089712558470876,51.754812,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2018",2018,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention with reperfusion therapy)",3,2,0,29,2,31,0,0,0,0,0,1.5709222164606,0.213333,0.010672,4.264527,2.46779661016949,0.75355,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2020",2020,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention with reperfusion therapy)",3,2,2,24,4,24,0,0,0,0,0,0.919486022435657,0.5,0.100918,2.477269,0.845454545454545,2.562783,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention with reperfusion therapy)",3,2,1,37,5,40,0,0,0,0,0,1.12086984362557,0.216216,0.026478,1.765612,1.25634920634921,1.51421,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Meng 2012",2012,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention with reperfusion therapy)",3,2,3,38,8,30,0,0,0,0,0,0.729629568588957,0.296053,0.085883,1.02054,0.532359307359307,4.170956,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Meng 2012",2012,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention with reperfusion therapy)",3,2,2,38,7,30,0,0,0,0,0,0.845052176794123,0.225564,0.050492,1.007664,0.714113181504486,2.912511,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Meng 2015",2015,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention with reperfusion therapy)",3,2,2,30,5,28,0,0,0,0,0,0.882718837786897,0.373333,0.078698,1.771037,0.779192546583851,2.701604,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Poalelungi 2021",2021,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention with reperfusion therapy)",3,2,1,18,0,22,0,0,0,0,0,1.66380707062266,3.631579,0.156808,84.105266,2.76825396825397,0.685372,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Blauenfeldt 2023",2023,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)",4,1,22,377,27,292,0,0,0,0,0,0.295949975887905,0.631103,0.367114,1.084924,0.0875863882280514,13.638841,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Che 2019",2019,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)",4,1,0,15,1,15,0,0,0,0,0,0,0.333333,0.01465,7.584305,0,0.535433,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2017",2017,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)",4,1,0,13,2,13,0,0,0,0,0,0,0.2,0.010525,3.800646,0,0.602207,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2019",2019,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)",4,1,2,31,6,29,0,0,0,0,0,0.931566472107076,0.311828,0.068331,1.423024,0.867816091954023,2.200914,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Guo 2025",2025,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)",4,1,35,270,34,266,0,0,0,0,0,0,1.014161,0.652808,1.575538,0,18.357753,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kerstens 2023",2023,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)",4,1,3,40,6,48,0,0,0,0,0,0,0.6,0.160144,2.247978,0,2.871367,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)",4,1,1,37,5,40,0,0,0,0,0,0,0.216216,0.026478,1.765612,0,1.171987,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Poalelungi 2021",2021,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)",4,1,1,18,0,22,0,0,0,0,0,0,3.631579,0.156808,84.105266,0,0.529471,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chen 2022",2022,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)",4,2,7,863,6,913,0,0,0,0,0,0,1.23426,0.416456,3.658004,0,4.143402,"4::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"He 2020",2020,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)",4,2,1,24,0,25,0,0,0,0,0,0,3.12,0.133275,73.039718,0,0.525895,"4::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2018",2018,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)",4,2,0,29,2,31,0,0,0,0,0,0,0.213333,0.010672,4.264527,0,0.582232,"4::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2020",2020,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)",4,2,2,24,4,24,0,0,0,0,0,0,0.5,0.100918,2.477269,0,1.988333,"4::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hou 2022",2022,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)",4,3,257,1517,288,1516,0,0,0,0,0,0.0777460379561084,0.891773,0.765732,1.038561,0.0060444464178726,45.245998,"4::3","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Meng 2012",2012,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)",4,3,2,38,7,30,0,0,0,0,0,0,0.225564,0.050492,1.007664,0,2.261479,"4::3","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Meng 2012",2012,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)",4,3,3,38,8,30,0,0,0,0,0,0,0.296053,0.085883,1.02054,0,3.247983,"4::3","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Meng 2015",2015,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)",4,3,2,30,5,28,0,0,0,0,0,0,0.373333,0.078698,1.771037,0,2.096703,"4::3","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Blauenfeldt 2023",2023,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)",5,1,22,377,27,393,0,0,0,0,0,0.295949975887905,0.849396,0.492561,1.464739,0.0875863882280514,7.390181,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Che 2019",2019,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)",5,1,0,15,1,15,0,0,0,0,0,1.67336436944866,0.333333,0.01465,7.584305,2.8001483129403,0.230999,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2017",2017,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)",5,1,0,13,2,13,0,0,0,0,0,1.60032202878458,0.2,0.010525,3.800646,2.5610305958132,0.260089,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2019",2019,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)",5,1,2,31,6,29,0,0,0,0,0,0.931566472107076,0.311828,0.068331,1.423024,0.867816091954023,0.975902,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Guo 2025",2025,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)",5,1,35,270,34,266,0,0,0,0,0,0,1.014161,0.652808,1.575538,0,11.141844,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"He 2020",2020,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)",5,1,1,24,0,25,0,0,0,0,0,1.65784062696947,3.12,0.133275,73.039718,2.74843554443054,0.226849,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kerstens 2023",2023,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)",5,1,3,40,6,48,0,0,0,0,0,0.742183636869307,0.6,0.160144,2.247978,0.550836550836551,1.287581,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2020",2020,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)",5,1,2,24,4,24,0,0,0,0,0,0.919486022435657,0.5,0.100918,2.477269,0.845454545454545,0.878528,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Poalelungi 2021",2021,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)",5,1,1,18,0,22,0,0,0,0,0,1.66380707062266,3.631579,0.156808,84.105266,2.76825396825397,0.228405,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Zhang 2022",2022,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)",5,1,0,19,1,22,0,0,0,0,0,1.66266663701889,0.383333,0.016525,8.892066,2.76446034585569,0.228172,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chen 2022",2022,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)",5,2,7,863,6,913,0,0,0,0,0,0.558385681814362,1.23426,0.416456,3.658004,0.311794569655289,1.898719,"5::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2018",2018,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)",5,2,0,29,2,31,0,0,0,0,0,1.5709222164606,0.213333,0.010672,4.264527,2.46779661016949,0.25138,"5::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)",5,2,1,37,5,40,0,0,0,0,0,1.12086984362557,0.216216,0.026478,1.765612,1.25634920634921,0.510902,"5::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hou 2022",2022,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)",5,3,257,1517,288,1516,0,0,0,0,0,0.0947167136628357,0.891773,0.765732,1.038561,0.0089712558470876,71.092822,"5::3","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Meng 2012",2012,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)",5,3,2,38,7,30,0,0,0,0,0,0.845052176794123,0.225564,0.050492,1.007664,0.714113181504486,1.00377,"5::3","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Meng 2012",2012,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)",5,3,3,38,8,30,0,0,0,0,0,0.729629568588957,0.296053,0.085883,1.02054,0.532359307359307,1.465773,"5::3","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Meng 2015",2015,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)",5,3,2,30,5,28,0,0,0,0,0,0.882718837786897,0.373333,0.078698,1.771037,0.779192546583851,0.928081,"5::3","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"An 2020",2020,"Excellent functional outcomes (mRS 0-1) at 90 days (for all studies)",1,NA,23,32,17,34,0,0,0,0,0,0,1.4375,0.963635,2.144387,0,6.702409,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chen 2022",2022,"Excellent functional outcomes (mRS 0-1) at 90 days (for all studies)",1,NA,582,863,566,913,0,0,0,0,0,0,1.087844,1.015552,1.165282,0,26.746894,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2019",2019,"Excellent functional outcomes (mRS 0-1) at 90 days (for all studies)",1,NA,9,31,11,29,0,0,0,0,0,0,0.765396,0.37223,1.573842,0,2.449169,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Guo 2025",2025,"Excellent functional outcomes (mRS 0-1) at 90 days (for all studies)",1,NA,168,268,150,264,0,0,0,0,0,0,1.103284,0.95918,1.269036,0,20.79316,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"He 2020",2020,"Excellent functional outcomes (mRS 0-1) at 90 days (for all studies)",1,NA,15,24,17,25,0,0,0,0,0,0,0.919118,0.60979,1.385359,0,6.441561,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hougaard 2014",2014,"Excellent functional outcomes (mRS 0-1) at 90 days (for all studies)",1,NA,96,133,66,91,0,0,0,0,0,0,0.995215,0.8441,1.173384,0,18.685439,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Landman 2023",2023,"Excellent functional outcomes (mRS 0-1) at 90 days (for all studies)",1,NA,20,31,19,40,0,0,0,0,0,0,1.358234,0.894664,2.062005,0,6.268385,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2018",2018,"Excellent functional outcomes (mRS 0-1) at 90 days (for all studies)",1,NA,7,29,5,31,0,0,0,0,0,0,1.496552,0.534334,4.191511,0,1.253133,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Meng 2012",2012,"Excellent functional outcomes (mRS 0-1) at 90 days (for all studies)",1,NA,25,38,4,30,0,0,0,0,0,0,4.934211,1.926125,12.64011,0,1.4895,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pico 2020",2020,"Excellent functional outcomes (mRS 0-1) at 90 days (for all studies)",1,NA,46,90,37,95,0,0,0,0,0,0,1.312312,0.950249,1.812329,0,9.17035,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2019",2019,"Subgroup analysis, excellent functional outcomes (mRS 0-1) at 90 days (based on unilateral or bilateral limb RIC intervention)",2,1,9,31,11,29,0,0,0,0,0,0.55048188256318,0.765396,0.37223,1.573842,0.303030303030303,2.449169,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Guo 2025",2025,"Subgroup analysis, excellent functional outcomes (mRS 0-1) at 90 days (based on unilateral or bilateral limb RIC intervention)",2,1,168,268,150,264,0,0,0,0,0,0.0714130628637838,1.103284,0.95918,1.269036,0.0050998255475867,20.79316,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"He 2020",2020,"Subgroup analysis, excellent functional outcomes (mRS 0-1) at 90 days (based on unilateral or bilateral limb RIC intervention)",2,1,15,24,17,25,0,0,0,0,0,0.601332942045871,0.919118,0.60979,1.385359,0.361601307189542,6.441561,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Landman 2023",2023,"Subgroup analysis, excellent functional outcomes (mRS 0-1) at 90 days (based on unilateral or bilateral limb RIC intervention)",2,1,20,31,19,40,0,0,0,0,0,0.491080153819625,1.358234,0.894664,2.062005,0.241159717475507,6.268385,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2018",2018,"Subgroup analysis, excellent functional outcomes (mRS 0-1) at 90 days (based on unilateral or bilateral limb RIC intervention)",2,1,7,29,5,31,0,0,0,0,0,0.653278827739907,1.496552,0.534334,4.191511,0.426773226773227,1.253133,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pico 2020",2020,"Subgroup analysis, excellent functional outcomes (mRS 0-1) at 90 days (based on unilateral or bilateral limb RIC intervention)",2,1,46,90,37,95,0,0,0,0,0,0.297883885934482,1.312312,0.950249,1.812329,0.0887348094994271,9.17035,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"An 2020",2020,"Subgroup analysis, excellent functional outcomes (mRS 0-1) at 90 days (based on unilateral or bilateral limb RIC intervention)",2,2,23,32,17,34,0,0,0,0,0,0.521762810867357,1.4375,0.963635,2.144387,0.272236430804206,6.702409,"2::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chen 2022",2022,"Subgroup analysis, excellent functional outcomes (mRS 0-1) at 90 days (based on unilateral or bilateral limb RIC intervention)",2,2,582,863,566,913,0,0,0,0,0,0.0996271085213732,1.087844,1.015552,1.165282,0.0099255607523294,26.746894,"2::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hougaard 2014",2014,"Subgroup analysis, excellent functional outcomes (mRS 0-1) at 90 days (based on unilateral or bilateral limb RIC intervention)",2,2,96,133,66,91,0,0,0,0,0,0.304294608636448,0.995215,0.8441,1.173384,0.0925952088452088,18.685439,"2::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Meng 2012",2012,"Subgroup analysis, excellent functional outcomes (mRS 0-1) at 90 days (based on unilateral or bilateral limb RIC intervention)",2,2,25,38,4,30,0,0,0,0,0,0.636698213743855,4.934211,1.926125,12.64011,0.405384615384615,1.4895,"2::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"An 2020",2020,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention with reperfusion therapy)",3,1,23,32,17,34,0,0,0,0,0,0.521762810867357,1.4375,0.963635,2.144387,0.272236430804206,8.572678,"3::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Guo 2025",2025,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention with reperfusion therapy)",3,1,168,268,150,264,0,0,0,0,0,0.0714130628637838,1.103284,0.95918,1.269036,0.0050998255475867,25.159487,"3::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"He 2020",2020,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention with reperfusion therapy)",3,1,15,24,17,25,0,0,0,0,0,0.601332942045871,0.919118,0.60979,1.385359,0.361601307189542,8.247755,"3::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hougaard 2014",2014,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention with reperfusion therapy)",3,1,96,133,66,91,0,0,0,0,0,0.304294608636448,0.995215,0.8441,1.173384,0.0925952088452088,22.793245,"3::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chen 2022",2022,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention with reperfusion therapy)",3,2,582,863,566,913,0,0,0,0,0,0.0996271085213732,1.087844,1.015552,1.165282,0.0099255607523294,31.64162,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2018",2018,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention with reperfusion therapy)",3,2,7,29,5,31,0,0,0,0,0,0.653278827739907,1.496552,0.534334,4.191511,0.426773226773227,1.638987,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Meng 2012",2012,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention with reperfusion therapy)",3,2,25,38,4,30,0,0,0,0,0,0.636698213743855,4.934211,1.926125,12.64011,0.405384615384615,1.946229,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"An 2020",2020,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)",4,1,23,32,17,34,0,0,0,0,0,0.521762810867357,1.4375,0.963635,2.144387,0.272236430804206,6.702409,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2019",2019,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)",4,1,9,31,11,29,0,0,0,0,0,0.55048188256318,0.765396,0.37223,1.573842,0.303030303030303,2.449169,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Guo 2025",2025,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)",4,1,168,268,150,264,0,0,0,0,0,0.0714130628637838,1.103284,0.95918,1.269036,0.0050998255475867,20.79316,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"He 2020",2020,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)",4,1,15,24,17,25,0,0,0,0,0,0.601332942045871,0.919118,0.60979,1.385359,0.361601307189542,6.441561,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hougaard 2014",2014,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)",4,1,96,133,66,91,0,0,0,0,0,0.304294608636448,0.995215,0.8441,1.173384,0.0925952088452088,18.685439,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Landman 2023",2023,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)",4,1,20,31,19,40,0,0,0,0,0,0.491080153819625,1.358234,0.894664,2.062005,0.241159717475507,6.268385,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pico 2020",2020,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)",4,1,46,90,37,95,0,0,0,0,0,0.297883885934482,1.312312,0.950249,1.812329,0.0887348094994271,9.17035,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chen 2022",2022,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)",4,2,582,863,566,913,0,0,0,0,0,0.0996271085213732,1.087844,1.015552,1.165282,0.0099255607523294,26.746894,"4::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2018",2018,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)",4,2,7,29,5,31,0,0,0,0,0,0.653278827739907,1.496552,0.534334,4.191511,0.426773226773227,1.253133,"4::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Meng 2012",2012,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)",4,3,25,38,4,30,0,0,0,0,0,0.636698213743855,4.934211,1.926125,12.64011,0.405384615384615,1.4895,"4::3","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2019",2019,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)",5,1,9,31,11,29,0,0,0,0,0,0.55048188256318,0.765396,0.37223,1.573842,0.303030303030303,2.449169,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Guo 2025",2025,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)",5,1,168,268,150,264,0,0,0,0,0,0.0714130628637838,1.103284,0.95918,1.269036,0.0050998255475867,20.79316,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"He 2020",2020,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)",5,1,15,24,17,25,0,0,0,0,0,0.601332942045871,0.919118,0.60979,1.385359,0.361601307189542,6.441561,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hougaard 2014",2014,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)",5,1,96,133,66,91,0,0,0,0,0,0.304294608636448,0.995215,0.8441,1.173384,0.0925952088452088,18.685439,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Landman 2023",2023,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)",5,1,20,31,19,40,0,0,0,0,0,0.491080153819625,1.358234,0.894664,2.062005,0.241159717475507,6.268385,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pico 2020",2020,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)",5,1,46,90,37,95,0,0,0,0,0,0.297883885934482,1.312312,0.950249,1.812329,0.0887348094994271,9.17035,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"An 2020",2020,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)",5,2,23,32,17,34,0,0,0,0,0,0.521762810867357,1.4375,0.963635,2.144387,0.272236430804206,6.702409,"5::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chen 2022",2022,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)",5,2,582,863,566,913,0,0,0,0,0,0.0996271085213732,1.087844,1.015552,1.165282,0.0099255607523294,26.746894,"5::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2018",2018,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)",5,2,7,29,5,31,0,0,0,0,0,0.653278827739907,1.496552,0.534334,4.191511,0.426773226773227,1.253133,"5::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Meng 2012",2012,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)",5,3,25,38,4,30,0,0,0,0,0,0.636698213743855,4.934211,1.926125,12.64011,0.405384615384615,1.4895,"5::3","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"An 2020",2020,"Treatment-related adverse events",1,NA,2,31,0,31,0,0,0,0,0,0,5,0.249792,100.083444,0,4.720468,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Blauenfeldt 2023",2023,"Treatment-related adverse events",1,NA,54,436,11,466,0,0,0,0,0,0.174031696529003,5.246872,2.780323,9.901608,0.0302870313967631,15.320379,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Che 2019",2019,"Treatment-related adverse events",1,NA,9,15,0,15,0,0,0,0,0,0,19,1.204834,299.626301,0,5.308144,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chen 2022",2022,"Treatment-related adverse events",1,NA,6,863,0,913,0,0,0,0,0,0,13.752315,0.775901,243.750235,0,5.009062,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2019",2019,"Treatment-related adverse events",1,NA,0,31,0,29,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Guo 2025",2025,"Treatment-related adverse events",1,NA,11,274,0,273,0,0,0,0,0,0,22.916364,1.357134,386.962425,0,5.130411,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"He 2020",2020,"Treatment-related adverse events",1,NA,6,63,4,63,0,0,0,0,0,0,1.5,0.44462,5.060501,0,11.954442,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"He 2022",2022,"Treatment-related adverse events",1,NA,6,63,4,63,0,0,0,0,0,1.50159148119832,1.5,0.44462,5.060501,2.25477697640736,11.954442,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hou 2022",2022,"Treatment-related adverse events",1,NA,123,1515,3,1514,0,0,0,0,0,0,40.972937,13.063553,128.508803,0,12.389866,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2018",2018,"Treatment-related adverse events",1,NA,1,29,0,31,0,0,0,0,0,0,3.2,0.135544,75.547658,0,4.362734,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2020",2020,"Treatment-related adverse events",1,NA,3,24,0,24,0,0,0,0,0,0,7,0.380999,128.609353,0,4.921471,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Treatment-related adverse events",1,NA,2,37,0,40,0,0,0,0,0,0,5.394737,0.267485,108.803155,0,4.703277,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Meng 2012",2012,"Treatment-related adverse events",1,NA,0,51,0,52,0,0,0,0,0,1.49920498663632,NA,NA,NA,2.24761559195521,NA,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Meng 2015",2015,"Treatment-related adverse events",1,NA,3,30,0,28,0,0,0,0,0,0,6.548387,0.353318,121.367616,0,4.900476,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pico 2020",2020,"Treatment-related adverse events",1,NA,4,94,0,94,0,0,0,0,0,0,9,0.491327,164.859503,0,4.928708,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Poalelungi 2021",2021,"Treatment-related adverse events",1,NA,0,18,0,22,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Zhang 2022",2022,"Treatment-related adverse events",1,NA,1,20,0,22,0,0,0,0,0,0,3.285714,0.14144,76.328626,0,4.39612,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"An 2020",2020,"Functional independence (mRS 0-2) at 90 days (for all studies)",1,NA,26,32,20,34,0,0,0,0,0,0,1.38125,0.996206,1.915117,0,3.142504,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Blauenfeldt 2023",2023,"Functional independence (mRS 0-2) at 90 days (for all studies)",1,NA,297,436,310,466,0,0,0,0,0,0,1.023986,0.934965,1.121484,0,18.318733,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chen 2022",2022,"Functional independence (mRS 0-2) at 90 days (for all studies)",1,NA,687,863,689,913,0,0,0,0,0,0,1.054866,1.003337,1.109042,0,25.53224,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2019",2019,"Functional independence (mRS 0-2) at 90 days (for all studies)",1,NA,19,31,15,29,0,0,0,0,0,0,1.184946,0.756062,1.85712,0,1.746085,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Guo 2025",2025,"Functional independence (mRS 0-2) at 90 days (for all studies)",1,NA,211,268,210,264,0,0,0,0,0,0,0.989765,0.907062,1.08001,0,18.929291,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"He 2020",2020,"Functional independence (mRS 0-2) at 90 days (for all studies)",1,NA,19,24,19,25,0,0,0,0,0,0,1.041667,0.770858,1.407612,0,3.636223,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hougaard 2014",2014,"Functional independence (mRS 0-2) at 90 days (for all studies)",1,NA,107,133,80,91,0,0,0,0,0,0,0.915132,0.817156,1.024854,0,14.977543,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Landman 2023",2023,"Functional independence (mRS 0-2) at 90 days (for all studies)",1,NA,24,31,30,40,0,0,0,0,0,0,1.032258,0.795077,1.340193,0,4.65485,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Functional independence (mRS 0-2) at 90 days (for all studies)",1,NA,17,37,6,40,0,0,0,0,0,0,3.063063,1.354066,6.929025,0,0.5508,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pico 2020",2020,"Functional independence (mRS 0-2) at 90 days (for all studies)",1,NA,62,90,60,91,0,0,0,0,0,0,1.044815,0.853117,1.279588,0,7.022581,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Zhang 2022",2022,"Functional independence (mRS 0-2) at 90 days (for all studies)",1,NA,12,19,13,22,0,0,0,0,0,0,1.068826,0.655645,1.74239,0,1.489151,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Blauenfeldt 2023",2023,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)",2,1,297,436,310,466,0,0,0,0,0,0.14211724326481,1.023986,0.934965,1.121484,0.0201973108331892,18.318733,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2019",2019,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)",2,1,19,31,15,29,0,0,0,0,0,0.5235075456724,1.184946,0.756062,1.85712,0.27406015037594,1.746085,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Guo 2025",2025,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)",2,1,211,268,210,264,0,0,0,0,0,0.0445198740264938,0.989765,0.907062,1.08001,0.0019820191833348,18.929291,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,FALSE
"He 2020",2020,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)",2,1,19,24,19,25,0,0,0,0,0,0.686971487444278,1.041667,0.770858,1.407612,0.471929824561403,3.636223,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Landman 2023",2023,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)",2,1,24,31,30,40,0,0,0,0,0,0.563788207447746,1.032258,0.795077,1.340193,0.317857142857143,4.65485,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pico 2020",2020,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)",2,1,62,90,60,91,0,0,0,0,0,0.317439835488783,1.044815,0.853117,1.279588,0.100768049155146,7.022581,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Zhang 2022",2022,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)",2,1,12,19,13,22,0,0,0,0,0,0.643602877731808,1.068826,0.655645,1.74239,0.414224664224664,1.489151,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"An 2020",2020,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)",2,2,26,32,20,34,0,0,0,0,0,0.571451464742874,1.38125,0.996206,1.915117,0.326556776556777,3.142504,"2::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chen 2022",2022,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)",2,2,687,863,689,913,0,0,0,0,0,0.114250106265442,1.054866,1.003337,1.109042,0.0130530867816646,25.53224,"2::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hougaard 2014",2014,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)",2,2,107,133,80,91,0,0,0,0,0,0.388865560011622,0.915132,0.817156,1.024854,0.151216423763153,14.977543,"2::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)",2,2,17,37,6,40,0,0,0,0,0,0.552179283190083,3.063063,1.354066,6.929025,0.304901960784314,0.5508,"2::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"An 2020",2020,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention with reperfusion therapy)",3,1,26,32,20,34,0,0,0,0,0,0.571451464742874,1.38125,0.996206,1.915117,0.326556776556777,7.899921,"3::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Guo 2025",2025,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention with reperfusion therapy)",3,1,211,268,210,264,0,0,0,0,0,0.0445198740264938,0.989765,0.907062,1.08001,0.0019820191833348,26.93359,"3::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,FALSE
"He 2020",2020,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention with reperfusion therapy)",3,1,19,24,19,25,0,0,0,0,0,0.686971487444278,1.041667,0.770858,1.407612,0.471929824561403,8.927,"3::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hougaard 2014",2014,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention with reperfusion therapy)",3,1,107,133,80,91,0,0,0,0,0,0.388865560011622,0.915132,0.817156,1.024854,0.151216423763153,23.908225,"3::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chen 2022",2022,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention with reperfusion therapy)",3,2,687,863,689,913,0,0,0,0,0,0.114250106265442,1.054866,1.003337,1.109042,0.0130530867816646,30.747202,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention with reperfusion therapy)",3,2,17,37,6,40,0,0,0,0,0,0.552179283190083,3.063063,1.354066,6.929025,0.304901960784314,1.584062,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"An 2020",2020,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)",4,1,26,32,20,34,0,0,0,0,0,0.571451464742874,1.38125,0.996206,1.915117,0.326556776556777,3.142504,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Blauenfeldt 2023",2023,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)",4,1,297,436,310,466,0,0,0,0,0,0.14211724326481,1.023986,0.934965,1.121484,0.0201973108331892,18.318733,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2019",2019,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)",4,1,19,31,15,29,0,0,0,0,0,0.5235075456724,1.184946,0.756062,1.85712,0.27406015037594,1.746085,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Guo 2025",2025,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)",4,1,211,268,210,264,0,0,0,0,0,0.0445198740264938,0.989765,0.907062,1.08001,0.0019820191833348,18.929291,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,FALSE
"He 2020",2020,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)",4,1,19,24,19,25,0,0,0,0,0,0.686971487444278,1.041667,0.770858,1.407612,0.471929824561403,3.636223,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hougaard 2014",2014,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)",4,1,107,133,80,91,0,0,0,0,0,0.388865560011622,0.915132,0.817156,1.024854,0.151216423763153,14.977543,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Landman 2023",2023,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)",4,1,24,31,30,40,0,0,0,0,0,0.563788207447746,1.032258,0.795077,1.340193,0.317857142857143,4.65485,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)",4,1,17,37,6,40,0,0,0,0,0,0.552179283190083,3.063063,1.354066,6.929025,0.304901960784314,0.5508,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pico 2020",2020,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)",4,1,62,90,60,91,0,0,0,0,0,0.317439835488783,1.044815,0.853117,1.279588,0.100768049155146,7.022581,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chen 2022",2022,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)",4,2,687,863,689,913,0,0,0,0,0,0.114250106265442,1.054866,1.003337,1.109042,0.0130530867816646,25.53224,"4::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Zhang 2022",2022,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)",4,2,12,19,13,22,0,0,0,0,0,0.643602877731808,1.068826,0.655645,1.74239,0.414224664224664,1.489151,"4::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Blauenfeldt 2023",2023,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)",5,1,297,436,310,466,0,0,0,0,0,0.14211724326481,1.023986,0.934965,1.121484,0.0201973108331892,18.318733,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2019",2019,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)",5,1,19,31,15,29,0,0,0,0,0,0.5235075456724,1.184946,0.756062,1.85712,0.27406015037594,1.746085,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Guo 2025",2025,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)",5,1,211,268,210,264,0,0,0,0,0,0.0445198740264938,0.989765,0.907062,1.08001,0.0019820191833348,18.929291,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,FALSE
"He 2020",2020,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)",5,1,19,24,19,25,0,0,0,0,0,0.686971487444278,1.041667,0.770858,1.407612,0.471929824561403,3.636223,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hougaard 2014",2014,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)",5,1,107,133,80,91,0,0,0,0,0,0.388865560011622,0.915132,0.817156,1.024854,0.151216423763153,14.977543,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Landman 2023",2023,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)",5,1,24,31,30,40,0,0,0,0,0,0.563788207447746,1.032258,0.795077,1.340193,0.317857142857143,4.65485,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pico 2020",2020,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)",5,1,62,90,60,91,0,0,0,0,0,0.317439835488783,1.044815,0.853117,1.279588,0.100768049155146,7.022581,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Zhang 2022",2022,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)",5,1,12,19,13,22,0,0,0,0,0,0.643602877731808,1.068826,0.655645,1.74239,0.414224664224664,1.489151,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"An 2020",2020,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)",5,2,26,32,20,34,0,0,0,0,0,0.571451464742874,1.38125,0.996206,1.915117,0.326556776556777,3.142504,"5::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chen 2022",2022,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)",5,2,687,863,689,913,0,0,0,0,0,0.114250106265442,1.054866,1.003337,1.109042,0.0130530867816646,25.53224,"5::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)",5,2,17,37,6,40,0,0,0,0,0,0.552179283190083,3.063063,1.354066,6.929025,0.304901960784314,0.5508,"5::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"An 2020",2020,"Intracerebral haemorrhagic events during follow-up",1,NA,1,32,1,34,0,0,0,0,0,0,1.0625,0.069334,16.282207,0,3.242391,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Che 2019",2019,"Intracerebral haemorrhagic events during follow-up",1,NA,1,15,0,15,0,0,0,0,0,0,3,0.131851,68.258743,0,2.474004,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chen 2022",2022,"Intracerebral haemorrhagic events during follow-up",1,NA,0,863,0,913,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"England 2019",2019,"Intracerebral haemorrhagic events during follow-up",1,NA,2,31,1,29,0,0,0,0,0,0,1.870968,0.179068,19.548552,0,4.387268,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Guo 2025",2025,"Intracerebral haemorrhagic events during follow-up",1,NA,16,265,15,266,0,0,0,0,0,0,1.070692,0.540504,2.120947,0,51.696968,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"He 2020",2020,"Intracerebral haemorrhagic events during follow-up",1,NA,1,24,4,25,0,0,0,0,0,0,0.260417,0.031305,2.166347,0,5.382105,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hou 2022",2022,"Intracerebral haemorrhagic events during follow-up",1,NA,5,1517,6,1516,0,0,0,0,0,0.607253335731154,0.832784,0.254702,2.722906,0.368756613756614,17.211249,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2020",2020,"Intracerebral haemorrhagic events during follow-up",1,NA,0,24,1,24,0,0,0,0,0,0,0.333333,0.014252,7.796078,0,2.430964,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Meng 2015",2015,"Intracerebral haemorrhagic events during follow-up",1,NA,0,30,0,28,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Pico 2020",2020,"Intracerebral haemorrhagic events during follow-up",1,NA,4,88,4,88,0,0,0,0,0,0,1,0.258195,3.87304,0,13.175051,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Poalelungi 2021",2021,"Intracerebral haemorrhagic events during follow-up",1,NA,0,18,0,22,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Zhang 2022",2022,"Intracerebral haemorrhagic events during follow-up",1,NA,0,19,0,22,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Che 2019",2019,"&nbsp;Improvement in neurological impairment at the endpoint (for all studies)",1,NA,0,15,0,15,-0.33,0.82,-1,1.64,0,0.473427220735493,0.67,-0.2579,1.5979,0.224133333333333,10.370015,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"England 2017",2017,"&nbsp;Improvement in neurological impairment at the endpoint (for all studies)",1,NA,0,13,0,13,-3.3,4.21,1.1,5.12,0,0,-4.4,-8.003288,-0.796712,0,3.290756,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"England 2019",2019,"&nbsp;Improvement in neurological impairment at the endpoint (for all studies)",1,NA,0,30,0,24,-3,3.8,-1.4,6.3,0,0,-1.6,-4.463885,1.263885,0,4.503449,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Guo 2025",2025,"&nbsp;Improvement in neurological impairment at the endpoint (for all studies)",1,NA,0,272,0,272,-4,3.7,-4,3.7,0,0.317272382513641,0,-0.621842,0.621842,0.100661764705882,11.323076,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"He 2020",2020,"&nbsp;Improvement in neurological impairment at the endpoint (for all studies)",1,NA,0,24,0,25,1.5,0.79,2,2.58,0,0,-0.5,-1.559578,0.559578,0,9.909788,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"He 2022",2022,"&nbsp;Improvement in neurological impairment at the endpoint (for all studies)",1,NA,0,63,0,63,-5.54,1.61,-3.2,1.73,0,0.297742831401184,-2.34,-2.923565,-1.756435,0.0886507936507936,11.425221,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Landman 2023",2023,"&nbsp;Improvement in neurological impairment at the endpoint (for all studies)",1,NA,0,38,0,45,-0.25,4.89,-1.25,4.5,0,0,1,-1.036162,3.036162,0,6.551117,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2018",2018,"&nbsp;Improvement in neurological impairment at the endpoint (for all studies)",1,NA,0,29,0,31,-3.39,2.79,-2.11,3.41,0,0,-1.28,-2.852274,0.292274,0,8.064456,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2020",2020,"&nbsp;Improvement in neurological impairment at the endpoint (for all studies)",1,NA,0,24,0,24,-6,2.41,-5.83,2.49,0,0,-0.17,-1.556377,1.216377,0,8.726842,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"&nbsp;Improvement in neurological impairment at the endpoint (for all studies)",1,NA,0,37,0,38,-6,5.19,-0.25,7.32,0,0,-5.75,-8.615884,-2.884116,0,4.499476,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Meng 2015",2015,"&nbsp;Improvement in neurological impairment at the endpoint (for all studies)",1,NA,0,30,0,28,-8.33,2.15,-6.28,2.66,0,0,-2.05,-3.300057,-0.799943,0,9.221796,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Pico 2020",2020,"&nbsp;Improvement in neurological impairment at the endpoint (for all studies)",1,NA,0,93,0,95,-0.59,0.78,-0.51,0.78,0,0,-0.08,-0.303007,0.143007,0,12.114008,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"England 2017",2017,"Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,1,0,13,0,13,-3.3,4.21,1.1,5.12,0,1.83844625033875,-4.4,-8.003288,-0.796712,3.37988461538462,3.290756,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"England 2019",2019,"Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,1,0,30,0,24,-3,3.8,-1.4,6.3,0,1.46119243542161,-1.6,-4.463885,1.263885,2.13508333333333,4.503449,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Guo 2025",2025,"Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,1,0,272,0,272,-4,3.7,-4,3.7,0,0.317272382513641,0,-0.621842,0.621842,0.100661764705882,11.323076,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"He 2020",2020,"Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,1,0,24,0,25,1.5,0.79,2,2.58,0,0.540610919855183,-0.5,-1.559578,0.559578,0.292260166666667,9.909788,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"He 2022",2022,"Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,1,0,63,0,63,-5.54,1.61,-3.2,1.73,0,0.297742831401184,-2.34,-2.923565,-1.756435,0.0886507936507936,11.425221,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Landman 2023",2023,"Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,1,0,38,0,45,-0.25,4.89,-1.25,4.5,0,1.0388771772802,1,-1.036162,3.036162,1.07926578947368,6.551117,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Li 2018",2018,"Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,1,0,29,0,31,-3.39,2.79,-2.11,3.41,0,0.802195263872401,-1.28,-2.852274,0.292274,0.64351724137931,8.064456,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Li 2020",2020,"Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,1,0,24,0,24,-6,2.41,-5.83,2.49,0,0.707348334745101,-0.17,-1.556377,1.216377,0.500341666666667,8.726842,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Pico 2020",2020,"Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,1,0,93,0,95,-0.59,0.78,-0.51,0.78,0,0.113781132048274,-0.08,-0.303007,0.143007,0.0129461460101867,12.114008,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Che 2019",2019,"Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,2,0,15,0,15,-0.33,0.82,-1,1.64,0,0.473427220735493,0.67,-0.2579,1.5979,0.224133333333333,10.370015,"2::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Li 2024",2024,"Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,2,0,37,0,38,-6,5.19,-0.25,7.32,0,1.46221265915647,-5.75,-8.615884,-2.884116,2.13806586059744,4.499476,"2::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Meng 2015",2015,"Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)",2,2,0,30,0,28,-8.33,2.15,-6.28,2.66,0,0.637795683062635,-2.05,-3.300057,-0.799943,0.406783333333333,9.221796,"2::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Che 2019",2019,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention with reperfusion therapy)",3,1,0,15,0,15,-0.33,0.82,-1,1.64,0,0.473427220735493,0.67,-0.2579,1.5979,0.224133333333333,13.044821,"3::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Guo 2025",2025,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention with reperfusion therapy)",3,1,0,272,0,272,-4,3.7,-4,3.7,0,0.317272382513641,0,-0.621842,0.621842,0.100661764705882,13.852466,"3::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"He 2020",2020,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention with reperfusion therapy)",3,1,0,24,0,25,1.5,0.79,2,2.58,0,0.540610919855183,-0.5,-1.559578,0.559578,0.292260166666667,12.638255,"3::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"He 2022",2022,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention with reperfusion therapy)",3,1,0,63,0,63,-5.54,1.61,-3.2,1.73,0,0.297742831401184,-2.34,-2.923565,-1.756435,0.0886507936507936,13.936401,"3::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"England 2017",2017,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention with reperfusion therapy)",3,2,0,13,0,13,-3.3,4.21,1.1,5.12,0,1.83844625033875,-4.4,-8.003288,-0.796712,3.37988461538462,5.238576,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Li 2018",2018,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention with reperfusion therapy)",3,2,0,29,0,31,-3.39,2.79,-2.11,3.41,0,0.802195263872401,-1.28,-2.852274,0.292274,0.64351724137931,10.888531,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Li 2020",2020,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention with reperfusion therapy)",3,2,0,24,0,24,-6,2.41,-5.83,2.49,0,0.707348334745101,-0.17,-1.556377,1.216377,0.500341666666667,11.539743,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Li 2024",2024,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention with reperfusion therapy)",3,2,0,37,0,38,-6,5.19,-0.25,7.32,0,1.46221265915647,-5.75,-8.615884,-2.884116,2.13806586059744,6.852138,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Meng 2015",2015,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention with reperfusion therapy)",3,2,0,30,0,28,-8.33,2.15,-6.28,2.66,0,0.637795683062635,-2.05,-3.300057,-0.799943,0.406783333333333,12.00907,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Che 2019",2019,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)",4,1,0,15,0,15,-0.33,0.82,-1,1.64,0,0.473427220735493,0.67,-0.2579,1.5979,0.224133333333333,10.370015,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"England 2017",2017,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)",4,1,0,13,0,13,-3.3,4.21,1.1,5.12,0,1.83844625033875,-4.4,-8.003288,-0.796712,3.37988461538462,3.290756,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"England 2019",2019,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)",4,1,0,30,0,24,-3,3.8,-1.4,6.3,0,1.46119243542161,-1.6,-4.463885,1.263885,2.13508333333333,4.503449,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Guo 2025",2025,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)",4,1,0,272,0,272,-4,3.7,-4,3.7,0,0.317272382513641,0,-0.621842,0.621842,0.100661764705882,11.323076,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"He 2020",2020,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)",4,1,0,24,0,25,1.5,0.79,2,2.58,0,0.540610919855183,-0.5,-1.559578,0.559578,0.292260166666667,9.909788,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"He 2022",2022,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)",4,1,0,63,0,63,-5.54,1.61,-3.2,1.73,0,0.297742831401184,-2.34,-2.923565,-1.756435,0.0886507936507936,11.425221,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Landman 2023",2023,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)",4,1,0,38,0,45,-0.25,4.89,-1.25,4.5,0,1.0388771772802,1,-1.036162,3.036162,1.07926578947368,6.551117,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Li 2024",2024,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)",4,1,0,37,0,38,-6,5.19,-0.25,7.32,0,1.46221265915647,-5.75,-8.615884,-2.884116,2.13806586059744,4.499476,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Pico 2020",2020,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)",4,1,0,93,0,95,-0.59,0.78,-0.51,0.78,0,0.113781132048274,-0.08,-0.303007,0.143007,0.0129461460101867,12.114008,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Li 2018",2018,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)",4,2,0,29,0,31,-3.39,2.79,-2.11,3.41,0,0.802195263872401,-1.28,-2.852274,0.292274,0.64351724137931,8.064456,"4::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Li 2020",2020,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)",4,2,0,24,0,24,-6,2.41,-5.83,2.49,0,0.707348334745101,-0.17,-1.556377,1.216377,0.500341666666667,8.726842,"4::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Meng 2015",2015,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)",4,3,0,30,0,28,-8.33,2.15,-6.28,2.66,0,0.637795683062635,-2.05,-3.300057,-0.799943,0.406783333333333,9.221796,"4::3","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Che 2019",2019,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)",5,1,0,15,0,15,-0.33,0.82,-1,1.64,0,0.473427220735493,0.67,-0.2579,1.5979,0.224133333333333,10.370015,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"England 2017",2017,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)",5,1,0,13,0,13,-3.3,4.21,1.1,5.12,0,1.83844625033875,-4.4,-8.003288,-0.796712,3.37988461538462,3.290756,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"England 2019",2019,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)",5,1,0,30,0,24,-3,3.8,-1.4,6.3,0,1.46119243542161,-1.6,-4.463885,1.263885,2.13508333333333,4.503449,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Guo 2025",2025,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)",5,1,0,272,0,272,-4,3.7,-4,3.7,0,0.317272382513641,0,-0.621842,0.621842,0.100661764705882,11.323076,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"He 2020",2020,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)",5,1,0,24,0,25,1.5,0.79,2,2.58,0,0.540610919855183,-0.5,-1.559578,0.559578,0.292260166666667,9.909788,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"He 2022",2022,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)",5,1,0,63,0,63,-5.54,1.61,-3.2,1.73,0,0.297742831401184,-2.34,-2.923565,-1.756435,0.0886507936507936,11.425221,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Landman 2023",2023,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)",5,1,0,38,0,45,-0.25,4.89,-1.25,4.5,0,1.0388771772802,1,-1.036162,3.036162,1.07926578947368,6.551117,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Li 2020",2020,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)",5,1,0,24,0,24,-6,2.41,-5.83,2.49,0,0.707348334745101,-0.17,-1.556377,1.216377,0.500341666666667,8.726842,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Pico 2020",2020,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)",5,1,0,93,0,95,-0.59,0.78,-0.51,0.78,0,0.113781132048274,-0.08,-0.303007,0.143007,0.0129461460101867,12.114008,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Li 2018",2018,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)",5,2,0,29,0,31,-3.39,2.79,-2.11,3.41,0,0.802195263872401,-1.28,-2.852274,0.292274,0.64351724137931,8.064456,"5::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Li 2024",2024,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)",5,2,0,37,0,38,-6,5.19,-0.25,7.32,0,1.46221265915647,-5.75,-8.615884,-2.884116,2.13806586059744,4.499476,"5::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Meng 2015",2015,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)",5,3,0,30,0,28,-8.33,2.15,-6.28,2.66,0,0.637795683062635,-2.05,-3.300057,-0.799943,0.406783333333333,9.221796,"5::3","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Blauenfeldt 2023",2023,"Cardiovascular events during follow-up (for all studies)",1,NA,57,435,62,466,0,0,0,0,0,0,0.984872,0.70446,1.376903,0,49.351287,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Che 2019",2019,"Cardiovascular events during follow-up (for all studies)",1,NA,0,15,1,15,0,0,0,0,0,0,0.333333,0.01465,7.584305,0,0.567519,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2017",2017,"Cardiovascular events during follow-up (for all studies)",1,NA,0,13,1,13,0,0,0,0,0,0,0.333333,0.014812,7.501364,0,0.571535,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2019",2019,"Cardiovascular events during follow-up (for all studies)",1,NA,0,30,0,24,0,0,0,0,0,1.65590058379177,NA,NA,NA,2.74200674340193,NA,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Hou 2022",2022,"Cardiovascular events during follow-up (for all studies)",1,NA,43,1517,53,1516,0,0,0,0,0,0,0.810786,0.54571,1.204622,0,35.349795,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2020",2020,"Cardiovascular events during follow-up (for all studies)",1,NA,0,24,1,24,0,0,0,0,0,0,0.333333,0.014252,7.796078,0,0.557646,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Cardiovascular events during follow-up (for all studies)",1,NA,10,37,16,40,0,0,0,0,0,0,0.675676,0.352225,1.296153,0,13.056997,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pico 2020",2020,"Cardiovascular events during follow-up (for all studies)",1,NA,0,94,1,94,0,0,0,0,0,0,0.333333,0.013752,8.079552,0,0.545221,"1::overall","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Blauenfeldt 2023",2023,"Cardiovascular events during follow-up (based on unilateral or bilateral limb RIC intervention)",2,1,57,435,62,466,0,0,0,0,0,0,0.984872,0.70446,1.376903,0,49.351287,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2017",2017,"Cardiovascular events during follow-up (based on unilateral or bilateral limb RIC intervention)",2,1,0,13,1,13,0,0,0,0,0,0,0.333333,0.014812,7.501364,0,0.571535,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2019",2019,"Cardiovascular events during follow-up (based on unilateral or bilateral limb RIC intervention)",2,1,0,30,0,24,0,0,0,0,0,0,NA,NA,NA,0,NA,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Li 2020",2020,"Cardiovascular events during follow-up (based on unilateral or bilateral limb RIC intervention)",2,1,0,24,1,24,0,0,0,0,0,0,0.333333,0.014252,7.796078,0,0.557646,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pico 2020",2020,"Cardiovascular events during follow-up (based on unilateral or bilateral limb RIC intervention)",2,1,0,94,1,94,0,0,0,0,0,0,0.333333,0.013752,8.079552,0,0.545221,"2::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Che 2019",2019,"Cardiovascular events during follow-up (based on unilateral or bilateral limb RIC intervention)",2,2,0,15,1,15,0,0,0,0,0,0,0.333333,0.01465,7.584305,0,0.567519,"2::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hou 2022",2022,"Cardiovascular events during follow-up (based on unilateral or bilateral limb RIC intervention)",2,2,43,1517,53,1516,0,0,0,0,0,0,0.810786,0.54571,1.204622,0,35.349795,"2::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Cardiovascular events during follow-up (based on unilateral or bilateral limb RIC intervention)",2,2,10,37,16,40,0,0,0,0,0,0,0.675676,0.352225,1.296153,0,13.056997,"2::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Che 2019",2019,"Cardiovascular events during follow-up ( based on RIC intervention with reperfusion therapy)",3,1,0,15,1,15,0,0,0,0,0,0,0.333333,0.01465,7.584305,0,1.132694,"3::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2017",2017,"Cardiovascular events during follow-up ( based on RIC intervention with reperfusion therapy)",3,2,0,13,1,13,0,0,0,0,0,0,0.333333,0.014812,7.501364,0,1.140709,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hou 2022",2022,"Cardiovascular events during follow-up ( based on RIC intervention with reperfusion therapy)",3,2,43,1517,53,1516,0,0,0,0,0,0,0.810786,0.54571,1.204622,0,70.553554,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2020",2020,"Cardiovascular events during follow-up ( based on RIC intervention with reperfusion therapy)",3,2,0,24,1,24,0,0,0,0,0,0,0.333333,0.014252,7.796078,0,1.112989,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Cardiovascular events during follow-up ( based on RIC intervention with reperfusion therapy)",3,2,10,37,16,40,0,0,0,0,0,0,0.675676,0.352225,1.296153,0,26.060053,"3::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Blauenfeldt 2023",2023,"Cardiovascular events during follow-up (based on RIC intervention timing)",4,1,57,435,62,466,0,0,0,0,0,0,0.984872,0.70446,1.376903,0,49.351287,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Che 2019",2019,"Cardiovascular events during follow-up (based on RIC intervention timing)",4,1,0,15,1,15,0,0,0,0,0,0,0.333333,0.01465,7.584305,0,0.567519,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2017",2017,"Cardiovascular events during follow-up (based on RIC intervention timing)",4,1,0,13,1,13,0,0,0,0,0,0,0.333333,0.014812,7.501364,0,0.571535,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2019",2019,"Cardiovascular events during follow-up (based on RIC intervention timing)",4,1,0,30,0,24,0,0,0,0,0,0,NA,NA,NA,0,NA,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Li 2024",2024,"Cardiovascular events during follow-up (based on RIC intervention timing)",4,1,10,37,16,40,0,0,0,0,0,0,0.675676,0.352225,1.296153,0,13.056997,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pico 2020",2020,"Cardiovascular events during follow-up (based on RIC intervention timing)",4,1,0,94,1,94,0,0,0,0,0,0,0.333333,0.013752,8.079552,0,0.545221,"4::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2020",2020,"Cardiovascular events during follow-up (based on RIC intervention timing)",4,2,0,24,1,24,0,0,0,0,0,0,0.333333,0.014252,7.796078,0,0.557646,"4::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hou 2022",2022,"Cardiovascular events during follow-up (based on RIC intervention timing)",4,3,43,1517,53,1516,0,0,0,0,0,0,0.810786,0.54571,1.204622,0,35.349795,"4::3","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Blauenfeldt 2023",2023,"Cardiovascular events during follow-up( based on the duration of RIC intervention)",5,1,57,435,62,466,0,0,0,0,0,0,0.984872,0.70446,1.376903,0,49.351287,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Che 2019",2019,"Cardiovascular events during follow-up( based on the duration of RIC intervention)",5,1,0,15,1,15,0,0,0,0,0,0,0.333333,0.01465,7.584305,0,0.567519,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2017",2017,"Cardiovascular events during follow-up( based on the duration of RIC intervention)",5,1,0,13,1,13,0,0,0,0,0,0,0.333333,0.014812,7.501364,0,0.571535,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"England 2019",2019,"Cardiovascular events during follow-up( based on the duration of RIC intervention)",5,1,0,30,0,24,0,0,0,0,0,0,NA,NA,NA,0,NA,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Li 2020",2020,"Cardiovascular events during follow-up( based on the duration of RIC intervention)",5,1,0,24,1,24,0,0,0,0,0,0,0.333333,0.014252,7.796078,0,0.557646,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Pico 2020",2020,"Cardiovascular events during follow-up( based on the duration of RIC intervention)",5,1,0,94,1,94,0,0,0,0,0,0,0.333333,0.013752,8.079552,0,0.545221,"5::1","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Cardiovascular events during follow-up( based on the duration of RIC intervention)",5,2,10,37,16,40,0,0,0,0,0,0,0.675676,0.352225,1.296153,0,13.056997,"5::2","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hou 2022",2022,"Cardiovascular events during follow-up( based on the duration of RIC intervention)",5,3,43,1517,53,1516,0,0,0,0,0,0,0.810786,0.54571,1.204622,0,35.349795,"5::3","CD012503_pub3_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
